MoonLake Immunotherapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.01.25	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab (GlobeNewswire)
13.11.24	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
07.11.24	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
09.09.24	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
07.08.24	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
10.06.24	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis (GlobeNewswire)
16.05.24	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
10.03.24	MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
04.03.24	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
29.02.24	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire)
26.02.24	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
14.11.23	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
05.11.23	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis (GlobeNewswire)
15.10.23	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hi (GlobeNewswire)
11.10.23	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Co (GlobeNewswire)
06.09.23	MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 (GlobeNewswire)
10.08.23	MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
25.07.23	MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts (GlobeNewswire)
28.06.23	MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares (GlobeNewswire)
26.06.23	MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
25.06.23	MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa (GlobeNewswire)
12.05.23	MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
03.05.23	MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply (GlobeNewswire)
19.04.23	MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today (GlobeNewswire)
20.03.23	MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update (GlobeNewswire)
14.11.22	MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update (GlobeNewswire)
26.09.22	MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
26.07.22	MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH (GlobeNewswire)
12.05.22	MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	53.56	3.72 %	K V
Sonova Hldg	318.50	3.11 %	K V
Part Grp Hldg	1’381.00	2.30 %	K V
Alcon	80.90	1.81 %	K V
Lonza Grp	580.40	1.79 %	K V
Nestle	74.18	-0.75 %	K V
Geberit	500.80	-0.91 %	K V
Kuehne+Nagel Int	204.60	-1.06 %	K V
Swisscom	506.50	-1.65 %	K V
Logitech Intl	79.90	-1.75 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu MoonLake Immunotherapeutics

Aktien Top/Flop

Meistgelesene Nachrichten